The FDA has approved Pfizer's Hympavzi for treating hemophilia A and B in patients aged 12 and older without inhibitors. This weekly injection reduces the activity of tissue factor pathway inhibitor, enhancing blood clotting. Hympavzi offers a new treatment option alongside gene therapies and other factor replacement drugs, showing superior results in lowering bleeding rates.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
